Although much is known about the identity of progenitor stages in murine lymphopoiesis, considerably less is understood about the critical stages of lymphoid commitment of human hematopoietic cells. Early models developed from murine studies assumed strictly dichotomous pathways of lineage commitment^[@R1]^. These concepts have evolved more recently into models of gradual loss of lineage potential that can occur via multiple alternative pathways, although the physiological relevance of lineage potential revealed in certain *in vitro* assays continues to be debated^[@R2]--[@R5]^. A stage in which murine bone marrow (BM) progenitors are "lymphoid primed" prior to complete loss of myeloid potential has been defined based on expression of the FLT3 cell surface receptor, and termed the Lymphoid-primed Multipotent Progenitor (LMPP)^2^.

Critical species-specific differences create challenges when translating knowledge of cellular hierarchies derived from murine studies to the specifics of human hematopoiesis^[@R6]^. In addition, the source and stage in ontogeny of human hematopoiesis can influence the functional capacity, surface immunophenotype and transcriptional profiles of the cells under study^[@R6]--[@R8]^. Most studies of the earliest progenitor stages in human hematopoiesis have used neonatal umbilical cord blood as the source of hematopoietic cells. However, to understand how lymphopoiesis is regulated during steady-state adult hematopoiesis it is necessary to directly study hematopoietic stem cells and progenitors from postnatal human BM^[@R8],[@R9]^.

The stepwise process of lymphoid differentiation from multipotent hematopoietic stem cells (HSCs) in human BM has been assumed to begin with the expression of the cell surface antigen CD10 (aka CALLA, MME) on CD34^+^ cells^[@R10]^. However, while CD34^+^lin^−^CD10^+^ cells can give rise to cells of all lymphoid lineages, subsequent work has shown that CD10 expression on progenitors is associated with a strong bias toward B cell potential and minimal T and natural killer (NK) cell potential^[@R11],[@R12]^. CD34^+^lin^−^CD10^+^ cells that lack expression of CD24 are precursors of the CD34^+^lin^−^ CD10^+^CD24^+^ population, but nonetheless show molecular evidence of B cell commitment with expression of *PAX5, EBF1* and *VPREB*^[@R12]^. Therefore, to understand the progenitor hierarchy of human lymphoid commitment, we sought to identify a stage of lymphoid priming that precedes B lymphoid commitment, either prior to or independent of CD10 expression.

L-selectin (CD62L) is expressed on lymphocytes and mediates homing to peripheral lymphoid organs^[@R13]^. Recent studies have reported that up-regulation of CD62L expression on c-Kit^+^lin^−^Sca1^+^ murine BM cells correlates with loss of erythroid and megakaryocyte potential and efficient thymic engraftment^[@R14]--[@R16]^. In this study we have identified a CD34^+^lin^−^CD10^−^ progenitor subpopulation in human BM that expressed high amounts of L-selectin and was devoid of clonogenic myeloid or erythroid potential. In stromal cultures these cells were able to generate B, NK and T cells as well as monocytic and dendritic cells, similar to the previously described LMPPs in murine BM^2^. CD34^+^lin^−^CD10^−^CD62L^hi^ ("CD10^−^CD62L^hi^") cells rapidly engrafted immune-deficient mice, producing B and myeloid cells. Despite evidence of lymphoid skewing, comprehensive molecular analysis revealed that CD10^−^CD62L^hi^ cells not only lacked B cell specific transcripts, but also had not initiated DNA recombination based on absent *RAG1*, *RAG2* and minimal *DNTT* expression. Genome-wide expression and functional analysis placed the CD10^−^CD62L^hi^ progenitor population as a developmental intermediate between the multi-potent CD34^+^lin^−^CD38^−^ population and the CD34^+^lin^−^CD10^+^ lymphoid progenitor.

We also find that primitive lymphoid-restricted CD34^+^CD1a^−^ progenitors in human thymus expressed CD62L, and that the vasculature at the cortico-medullary junction of human thymus expressed ligands for CD62L, suggesting the possibility that L-selectin may play a role human thymic homing. We propose that the CD10^−^CD62L^hi^ progenitor in BM represents the earliest stage at which adult human progenitors become lymphoid-primed. The identification of this progenitor population will facilitate a more complete understanding of the regulation of lymphoid commitment from HSCs during normal and aberrant human hematopoiesis.

RESULTS {#S1}
=======

CD7 expression does not define lymphoid commitment {#S2}
--------------------------------------------------

In view of previous studies by our group and others linking CD7 expression to early stages of lymphoid commitment in umbilical cord blood^[@R17]--[@R20]^, we first investigated if expression of CD7 was sufficient to identify human lymphoid commitment in bone marrow, independent of CD10 expression. Examination of lineage-depleted cells revealed that the CD34^+^lin^−^CD38^−^CD7^+^ population previously identified in umbilical cord blood^[@R17]^ was not detectable in human BM ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). However, as previously noted^[@R7]^, low expression of CD7 was detected on a small (2.8 ± 0.6%, *n* = 5) population of CD34^+^lin^−^CD38^+^ human BM cells, most of which did not co-express CD10 ([Fig. 1a](#F1){ref-type="fig"}). Clonogenic assays demonstrated that CD7 expression alone was insufficient to define lymphoid restriction within the CD34^+^lin^−^CD10^−^ population of BM; non-lymphoid clonogenic cells, particularly erythroid progenitors, were readily detectable in the CD34^+^lin^−^CD10^−^CD7^+^ population by Colony Forming Unit-Cell (CFU-C) assay ([Fig. 1b](#F1){ref-type="fig"}). Consistent with previous studies in BM and umbilical cord blood^[@R7],[@R10]--[@R12],[@R21]^, CD34^+^lin^−^CD10^+^ progenitors were devoid of clonogenic myeloid and erythroid progenitors ([Fig. 1b](#F1){ref-type="fig"}).

L-selectin^hi^ progenitors do not possess CFU potential {#S3}
-------------------------------------------------------

CD45RA has previously been shown to be expressed on various lymphoid progenitors^[@R10],[@R17]--[@R19]^ and granulocyte-macrophage progenitors (GMPs)^[@R22]^. Analysis of the CD34^+^lin^−^CD10^−^ subpopulation demonstrated the presence of both CD45RA^−^ and CD45RA^+^ fractions; in contrast all CD34^+^lin^−^CD10^+^ cells expressed CD45RA ([Fig. 1c](#F1){ref-type="fig"}). Erythroid potential was depleted, but clonogenic myeloid progenitors (CFU-GM) were still readily detectable, in the CD34^+^lin^−^CD10^−^CD45RA^+^ population ([Fig. 1d](#F1){ref-type="fig"}). As expected, erythroid potential was high in CFU-C from megakarocytic-erythroid progenitors (MEPs) and common myeloid progenitors (CMPs) ([Fig. 1d](#F1){ref-type="fig"}), neither of which express CD45RA.

Further refinement of the CD10^−^CD45RA^+^ population was necessary to identify those cells that lacked clonogenic myeloid potential. L-selectin (CD62L) is a cell surface receptor that mediates lymphocyte homing to peripheral nodes^[@R13]^ and which is expressed on certain murine BM progenitors that lack erythroid or megakaryocytic potential^[@R14]^. Analysis of the CD34^+^lin^−^CD10^−^ CD45RA^+^population demonstrated that although most cells dimly expressed CD62L, a distinct subpopulation (9 ± 1.5%, *n* = 14) of CD34^+^lin^−^CD10^−^CD45RA^+^ cells in normal human BM highly expressed CD62L ([Fig. 1c](#F1){ref-type="fig"}). Functional screening of CD34^+^lin^−^ fractions in CFU-C assay demonstrated that only the CD34^+^lin^−^CD10^−^CD45RA^+^CD62L^hi^ ("CD10^−^CD62L^hi^ ") population and the CD34^+^lin^−^CD10^+^("CD10^+^") population were devoid of clonogenic myelo-erythroid potential ([Fig. 1d](#F1){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Of note, the CD34^+^lin^−^CD10^−^CD45RA^+^ population that expressed intermediate amounts of CD62L contained low but detectable CFU-C potential, suggesting that progressive loss of multi-potency correlates with increasing CD62L expression (population B, [Supplementary Fig. 1b,c](#SD1){ref-type="supplementary-material"}).

CD10^+^ cells expressed low or undetectable amounts of CD62L, and the CD34^+^lin^−^CD38^−^ population, which is highly enriched for HSC and multipotent progenitor cells (MPPs), showed intermediate expression of CD62L ([Fig. 1e](#F1){ref-type="fig"}, [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). Notably, CD10^−^ CD62L^hi^ cells did not express CD7 ([Fig. 1f](#F1){ref-type="fig"}). Thus, the progenitor subset with highest CD62L expression expressed neither CD10 nor CD7, markers previously relied upon for the isolation of human lymphoid progenitors. Analysis of BM from 20 different individuals from infancy to adulthood consistently showed the presence of CD10^−^ CD62L^hi^ cells ([Supplementary Fig. 2a--c](#SD1){ref-type="supplementary-material"}).

Lymphoid and monocyte potential of CD10^−^CD62L^hi^ cells {#S4}
---------------------------------------------------------

Culture in lymphoid conditions demonstrated that the CD10^−^ CD62L^hi^ population robustly generated both B and NK cells ([Fig. 2a](#F2){ref-type="fig"}). Consistent with previous studies, CD10^+^ cells (all of which were CD19^−^ through lineage depletion) generated mostly B cells with relatively weak NK potential^[@R11]^. Cell output under B-NK lymphoid conditions tended to be higher in cultures initiated with CD10^−^ CD62L^hi^ than with CD10^+^ cells ([Fig. 2b](#F2){ref-type="fig"}). Following *in vitro* culture under T cell conditions, CD10^−^CD62L^hi^ cells generated cells with the immunophenotype typical of thymocytes (expressing CD1A, CD7, CD4, CD8, CD3, TCRαβ)^[@R23]^ ([Fig. 2c,d](#F2){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), and expressing the T cell associated genes *TCF7, GATA3, DNTT* and *RAG1* ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}) as well as CD56^+^ NK cells (some of which co-expressed CD8). Cell output was significantly higher in T cell cultures initiated with CD10^−^CD62L^hi^ than with CD10^+^ cells (*P* = 0.038) ([Fig. 2e](#F2){ref-type="fig"}).

Although clonogenic myeloid cells were not detected in CFU-C assay, both the CD10^+^ and CD10^−^ CD62L^hi^ subsets were able to generate relatively low numbers of myeloid cells when cultured on stromal layers; however cell output from both progenitor types was significantly reduced relative to HSC-MPPs (*P* \< 0.0001) ([Fig. 2f](#F2){ref-type="fig"}). The majority of the non-lymphoid cells generated in stromal co-culture from the CD10^+^ and CD10^−^CD62L^hi^ populations were CD14^+^CD33^+^ monocyte-macrophages or CD209^+^CD1a^+^ dendritic cells ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}); CD66b^+^ granulocytes were uncommon. Erythroid differentiation was rarely seen from CD10^+^ or CD10^−^CD62L^hi^ cultures but was robust in cultures from CD38^−^ HSC-MPPs.

Cloning efficiency of CD10^−^CD62L^hi^ cells in lymphoid cultures initiated with single cells (\~11%) and by limiting dilution analysis (1 in 5.3 for B-NK and 1 in 5.6 for T cell cultures) ([Fig. 3a,b](#F3){ref-type="fig"}) was similar to that of CD10^+^ cells (\~12% from single cells). However lineage analysis of clones demonstrated that the CD10^−^CD62L^hi^ population contained bi-potent B-NK progenitors whereas the CD10^+^ population contained predominantly unipotent B cell progenitors ([Fig. 3c](#F3){ref-type="fig"}). Myeloid cells were detected in 86% of clones that could be assigned lineages in B-NK conditions ([Fig. 3d](#F3){ref-type="fig"}) and 97% of all clones assayed from T cell cultures ([Fig. 3e](#F3){ref-type="fig"}).

Consistent with the *in vitro* assays of lineage potential, intratibial transplantation of CD10^−^CD62L^hi^ progenitors into immune-deficient (NOD--SCID--IL-2Rγ^−/−^) mice produced rapid marrow engraftment of both myeloid and B lymphoid cells ([Fig. 3f,g](#F3){ref-type="fig"} and [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). T lymphoid differentiation from non-self renewing progenitors would not be expected in this xenogeneic adult mouse model.

In summary, functional assays showed that the CD10^−^CD62L^hi^ population possessed full T, B and NK lymphoid potential, was less skewed toward the B lineage than the CD10^+^ population, and had greater T potential than CD10^+^ population. Although depleted of clonogenic myelo-erythroid potential, some myeloid (mostly monocyte-macrophage and dendritic cell) differentiation could be induced in stromal co-cultures from the CD10^−^CD62L^hi^ population, and in short term engraftment assays. However, myeloid potential was markedly decreased relative to that of HSC-MPPs and erythroid potential was absent.

Differentiation stages of HSCs and lymphoid progenitors {#S5}
-------------------------------------------------------

In view of the lineage potential shown in the functional studies, we next explored the relative stages of differentiation of the CD10^−^CD62L^hi^ and CD10^+^ populations when compared to the most primitive CD34^+^lin^−^CD38^−^ ("CD38-") HSC-MPP population. Expression of the differentiation marker CD38 rose progressively from the CD34^+^CD38^−^ to the CD10^−^CD62L^hi^ population and was maximal in the CD10^+^ population (*n* = 14) ([Fig. 4a](#F4){ref-type="fig"}). Expression of the stem cell-associated receptors KIT, FLT3, ITGA6 (aka CD49f) and PROM1 (aka CD133) was similar in CD38^−^ and CD10^−^CD62L^hi^ populations but down-regulated in CD10^+^ cells; THY1 (aka CD90) was most highly expressed on CD38^−^ cells. HLA-DR was up-regulated in both CD10^−^CD62L^hi^ and CD10^+^ progenitors ([Fig. 4a](#F4){ref-type="fig"}). After one week in lymphoid cultures, CD10^+^ cells differentiated and lost CD34 expression faster than CD10^−^CD62L^hi^ cells ([Fig. 4b](#F4){ref-type="fig"}). In addition, CD10^−^CD62L^hi^ cells were able to generate CD34^+^CD10^+^ cells *in vitro*, suggesting that CD10^−^CD62L^hi^ cells are precursors to the CD10^+^ population ([Fig. 4b](#F4){ref-type="fig"}).

Principal components analysis performed on global gene expression data from microarrays on three different BM samples also placed the CD10^−^CD62L^hi^ progenitors in an intermediate position between the CD38^−^ HSC-MPPs and the CD10^+^ progenitors ([Fig. 4c](#F4){ref-type="fig"}). Gene expression of CD10^−^CD62L^hi^ progenitors clustered hierarchically with CD38^−^ HSC-MPPs rather than with CD10^+^ progenitors ([Supplemental Fig. 6a](#SD1){ref-type="supplementary-material"}). In pairwise comparison to HSC-MPPs, similar numbers of genes were up-regulated in CD10^−^CD62L^hi^ and CD10^+^ populations; approximately half of these up-regulated genes were common to both progenitor types ([Supplemental Fig. 6b](#SD1){ref-type="supplementary-material"}). More than twice as many genes were down-regulated in the CD10^+^ population than were down-regulated in the CD10^−^CD62L^hi^ population, and most downregulated genes in CD10^−^CD62L^hi^ cells were also downregulated in CD10^+^ cells ([Supplemental Fig. 6b](#SD1){ref-type="supplementary-material"}). Thus differentiation of HSC-MPPs involves many shared molecular pathways but additional transcriptional modulation appears to occur after the CD10^−^CD62L^hi^ stage during the generation of CD10^+^ cells.

Downregulation of HSC-associated genes in CD10^−^CD62L^hi^ cells {#S6}
----------------------------------------------------------------

Analysis of expression patterns of genes known to regulate critical hematopoietic stages of differentiation was then performed by microarray and quantitative PCR (qPCR) to dissect the molecular relationships amongst CD38^−^, CD10^−^CD62L^hi^, and CD10^+^ populations. All genes included in the heatmaps were at least 2-fold differentially expressed (*P* \<0.05), and belonged to one of 6 different expression patterns (clusters 1--6) ([Fig. 5a,b](#F5){ref-type="fig"}). Known HSC-related transcription factors (*TAL1, GATA2,* and *PRDM16*) were significantly down-regulated in both the CD10^−^CD62L^hi^ and CD10^+^ cells relative to the CD38^−^ population (cluster 1, [Fig. 5a](#F5){ref-type="fig"}). *HOXB* genes were also downregulated during the transition of the CD38^−^ HSC-MPP to the CD10^−^CD62L^hi^ LMPP stage with no significant further change at the CD10^+^ stage (cluster 1). In contrast, expression of *HOXA* genes decreased later in differentiation at the CD10^+^ progenitor stage (cluster 2 and 3). Reciprocal patterns of expression were seen for members of the polycomb repressive complexes PRC1 (*PCGF2, PHC2,* and *SCML4*) (cluster 1) and PRC2 (*SUZ12*, *EZH2* and *EED*) (cluster 5)^[@R24]^. These analyses reveal a highly coordinated program of transcriptional regulation as HSC lose multipotency, become lymphoid-primed and then commit to B lymphopoiesis.

Lymphoid differentiation stages of CD10-CD62L^hi^ and CD10^+^ cells {#S7}
-------------------------------------------------------------------

Analyses of genes up-regulated only in the CD10^−^ CD62L^hi^ population (Cluster 4) revealed a profile consistent with the dual lymphoid and monocyte potential of this population. Specifically, early T and NK lineage-associated genes (*CD2* and *CD3E)*^[@R14],[@R25]--[@R27]^ and lymphoid cytokine receptors (*IL2RG, IL10RA, IL10RB, IL17RA, IFNGR1*) were up-regulated, as were myeloid associated genes (*MPO, CSF1R,* and *CSF2R)* ([Fig 5b, c](#F5){ref-type="fig"}). Consistent with its cell surface expression, *FLT3* was expressed in both HSC-MPP and CD10^−^ CD62L^hi^ cells but not CD10^+^ cells (cluster 3, [Fig 5b](#F5){ref-type="fig"}).

Consistent with the B cell skewed differentiation potential of the CD10^+^ population, genes known to be expressed specifically during B cell commitment (*EBF1, PAX5, IL-7R, CD79A, CD79B, VPREB1, VPREB3, CD19, CD22, CD24, CD27*) were highly expressed in CD10^+^ cells (Cluster 6, [Fig. 5a--c](#F5){ref-type="fig"}). Notably, none of these B cell specific genes were expressed in either the CD34^+^CD38^−^ or CD10^−^ CD62L^hi^ cells.

A detailed analysis by qPCR showed that although expression of genes essential for lymphoid commitment was highest in CD10^+^ cells, up-regulation of certain early lymphoid genes began at the CD10^−^ CD62L^hi^ stage. *TCF3* (aka *E2A*) expression was 2.1-fold increased during the transition from CD38^−^ to CD10^−^ CD62L^hi^ (*P* = 0.003) and 4.4-fold increased in the transition from CD10^−^ CD62L^hi^ to CD10^+^ (*P* = 0.058) cells ([Fig. 5c](#F5){ref-type="fig"}). Similarly *DNTT* (aka *TDT*) was 8.0-fold increased in CD10^−^CD62L^hi^ (*P* = 0.002) and 12.0-fold further increased in CD10^+^ cells (*P* = 0.027) ([Fig. 5c](#F5){ref-type="fig"}). In contrast, *RAG1* expression was limited to CD10^+^ cells, demonstrating that the mechanisms of DNA rearrangement for T cell receptor and immunoglobulin are not fully initiated in the CD10^−^ CD62L^hi^ population ([Fig. 5c](#F5){ref-type="fig"}).

To investigate further the degree of heterogeneity within the three populations, the expression of key genes was assayed in single cells ([Fig. 5d](#F5){ref-type="fig"}). These analyses showed that the HSC genes *TAL1* (aka *SCF*) and *MPL* were expressed exclusively in CD38^−^ cells, and *RAG1* and *PAX5* expression was limited to CD10^+^ cells. *TCF3* was detected at a similar frequency in CD10^−^ CD62L^hi^ and CD10^+^ cells. Detectable *FLT3* expression in single cells was limited almost exclusively to the CD10^−^ CD62L^hi^ population ([Fig. 5d](#F5){ref-type="fig"}). Thus the CD38^−^ HSC-MPP, CD10^−^ CD62L^hi^ and CD10^+^ populations have distinct molecular profiles, consistent with their functional readout *in vitro*. Whereas the CD10^+^ population is committed to B lymphopoiesis, the CD10^−^ CD62L^hi^ population contains cells with evidence of early lymphoid priming but no expression of B lineage commitment genes ([Supplemental Fig. 7](#SD1){ref-type="supplementary-material"}).

L-selectin and ligand expression in human thymus {#S8}
------------------------------------------------

Co-expression of receptor-ligand pairs, previously reported in murine studies as important in thymic homing and settling, were analyzed by flow cytometry and gene expression. The chemokine receptor CXCR4 was expressed at similar abundance in CD10^−^ CD62L^hi^ and CD10^+^ populations ([Fig. 6a](#F6){ref-type="fig"}). However PSGL-1, the ligand for P-selectin, and CD44, were both expressed in CD10^−^ CD62L^hi^ cells at higher amounts than in CD10^+^ cells ([Fig. 6a](#F6){ref-type="fig"}). In addition, the gene encoding the chemokine receptor CCR7, which is expressed on murine early thymic progenitors and mediates migration of early thymocytes^[@R28]--[@R30]^, was significantly up-regulated in the CD10^−^ CD62L^hi^ population relative to both CD10^+^ cells (*P*\< 0.001) and CD38^−^ population (*P* \< 0.001) ([Fig. 6b](#F6){ref-type="fig"}). No consistent differences between the populations were seen in expression of the chemokine CCR9 (data not shown).

The expression of CD62L in progenitor populations from human thymus was next examined. CD62L expression was higher in CD34^+^ thymic progenitors than the more mature CD34^−^ thymocytes (which represent \>95% of all thymocytes) ([Fig. 6c](#F6){ref-type="fig"}). Upon further dissection of the CD34^+^ thymocyte population, the majority of CD62L expressing cells were within the CD34^+^CD1a^−^ subset rather than the more mature CD34^+^CD1a^+^ subset ([Fig. 6c](#F6){ref-type="fig"}). MECA79 detects a carbohydrate epitope that is found on a family of CD62L ligands known as peripheral node addressins (PNAds)^[@R31]^. MECA79 staining was detected in the thymic vasculature specifically in a subset of P-selectin^+^ endothelial cells at the cortico-medullary junction, the site of entry into the thymus of marrow-derived precursors ([Fig. 6d--j](#F6){ref-type="fig"}), suggesting a possible role for L-selectin in homing to human thymus.

DISCUSSION {#S9}
==========

The studies presented here demonstrate for the first time that "lymphoid priming" in human BM begins prior to the onset of CD10 expression, in a subset of CD34^+^ progenitors that highly express the homing molecule L-selectin. Several pieces of evidence argue strongly that the CD10^−^ CD62L^hi^ population is a precursor of the more B cell-restricted, CD10^+^ stage of lymphopoiesis. First, it is widely assumed that all human B cell differentiation passes through a CD10^+^ progenitor stage, and cultures initiated with CD10^−^ CD62L^hi^ cells were able to generate CD10^+^ progenitors prior to differentiating into CD19^+^ B cells. In addition, although the CD10^−^ CD62L^hi^ population contained greater NK potential, the number of B cells generated in culture was at least equivalent to those from CD10^+^ cultures. Patterns of gene and cell surface antigen expression were also consistent with the model that positions the CD10^−^ CD62L^hi^ population prior to CD10 expression.

A recent study described a CD10^+^ subset within the CD34^+^CD38^−/lo^ population with lymphoid, monocytic and dendritic cell, but no erythroid potential^[@R21]^. However, this CD10^+^ "multi-lymphoid progenitor" (MLP) also expressed the B cell specific gene *PAX5*. It should be noted that the MLP isolation strategy included cells with intermediate expression of CD38, similar to those expressed in the CD10^−^ CD62L^hi^ population, and higher than in the most primitive HSC fraction. We propose that lymphoid priming begins with upregulation of CD38 (relative to HSCs), and B cell commitment is initiated with the onset of CD10 and further upregulation of CD38 expression.

The vast majority of human hematopoietic studies have used umbilical cord blood (UCB), largely because this source of human cells is more readily accessible than BM. BM progenitors have substantially lower proliferative output than their immunophenotypic homologs in UCB^[@R7],[@R17],[@R32]--[@R34]^, or than HSC from either source^[@R35]^, making *in vivo* assessment of rare, non-self renewing BM progenitor populations difficult and sometimes unfeasible. However, UCB does not represent steady-state postnatal hematopoiesis and substantial differences in immunophenotype and function are known to exist between progenitors from UCB and BM^[@R6]^. Interestingly, we note that functional and molecular profiles in CD10^−^ CD62L^hi^ BM progenitors (which do not express CD7) are similar to CD34^+^CD38^−^ CD7^+^ UCB progenitors ^[@R20]^. We also note that the CD10^−^ CD62L^hi^ immunophenotype described here is less reliable for the identification of a pure lymphoid-primed population in UCB than in BM; a clear CD62L^hi^ population is difficult to detect in UCB, and CD34^+^lin^−^ CD10^−^ CD45RA^+^CD62L^+^ cells in UCB contain small but readily detectable numbers of CFU (Q-L.H. & G.M.C., unpublished data). The differences in lineage potentials of cells with similar immunophenotypes in UCB and BM, as well as the intrinsic functional differences that would be expected between cells that are detected transiently in the postnatal circulation and those that are generated throughout life in the BM microenvironment, highlight the critical need for studies that focus on human BM.

A large amount of elegant data has been generated in murine studies to argue both for and against the classical concept that the lymphoid and the myelo-erythroid pathways emerge separately from a multipotent progenitor stage^[@R1]--[@R4],[@R36]^. The "lymphoid-primed" LMPP in murine BM retain full lymphoid and some myeloid potential but have lost erythro-megakaryocytic potential, whereas common lymphoid progenitors (CLPs) represent a more mature, lymphoid-restricted progenitor population. FLT3 cell surface expression has been used to isolate LMPPs from a subpopulation of cKit^+^Lin^−^Sca1^+^ cells in murine BM^2^ and IL-7Rα is used to define murine CLPs within the cKit^−^Lin^−^Sca1^lo^ population^[@R1]^. Based on our functional and molecular data, the CD10^−^CD62L^hi^ human BM progenitor appears most similar to the murine LMPPs, and the CD10^+^ progenitor is more analogous to the murine CLPs. However, despite *FLT3* upregulation at the transcriptional level, we and others^[@R21]^ have not found the cell surface expression of FLT3 to be useful as a marker to discriminate between human HSCs and LMPPs. Interestingly, recent studies have reported that up-regulation of CD62L expression in cKit^+^Lin^−^Sca1^+^ murine BM cells correlates with high expression of FLT3 and loss of erythroid and megakaryocyte potential, thus suggesting that CD62L expression might be used as an alternative marker to discriminate between murine multipotent progenitors and LMPPs^[@R14]^.

The myeloid potential of the CD10^−^CD62L^hi^ population consisted mostly of monocyte-macrophage and dendritic cells. The absence of clonogenic myeloid-erythroid potential in CFU assays suggests strongly that the CD10^−^CD62L^hi^ population does not represent a precursor to the major myelo-erythroid pathways that are initiated by CMPs and GMPs. Rather we favor the concept that the CD10^−^CD62L^hi^ cells are "lymphoid-primed" progenitors that precede CD10 expression and which are able to generate limited numbers of monocyte-macrophage and dendritic cells. This type of residual myeloid and dendritic potential has been reported by several groups using even more lymphoid-committed progenitors^[@R10],\ [@R17],[@R21]^. An earlier paper noted that murine IL-7Rα^+^ CLPs, despite their complete lack of either CFU activity or *in vivo* myeloid potential, could generate myeloid cells in stromal co-cultures, suggesting that myeloid differentiation may be an alternative pathway revealed in certain *in vitro* conditions^[@R5]^. Nonetheless, it is clear that the capacity for myeloid differentiation *in vitro* progressively wanes as lymphoid commitment proceeds and that this residual, mostly monocytic, potential is retained after erythroid potential is lost.

We note both differences and similarities in gene expression between the CD10^−^CD62L^hi^ cells and the previously described murine LMPPs^[@R2],[@R36]^. In both murine LMPPs and human CD10^−^CD62L^hi^ cells, genes encoding the transcription factor TAL-1 and the cytokine receptor MPL are significantly down-regulated relative to HSCs, while *KIT* expression is retained^[@R36],[@R37]^. *E2A* expression, which is essential for the development of murine LMPPs^[@R38]^, is also up-regulated during generation of the CD10^−^CD62L^hi^ population from HSC-MPPs, but B cell-specific genes such as *EBF1* and *PAX5* are not. In contrast, the molecular machinery required for DNA recombination appears to be highly expressed in murine LMPPs^[@R36]^, but in our human studies, *RAG1* and *RAG2* were expressed at the CD10^+^ stage and *DNTT* expression in the CD10^+^ cells was significantly higher than in CD10^−^CD62L^hi^ cells.

The identification of a lymphoid primed precursor to the previously described CD10^+^ "CLP", begs the question of whether the CD10^−^ CD62L^hi^ cells are recruited to the thymus to initiate T cell differentiation. Controversy regarding the identity of precursors that seed the murine thymus has continued for over a decade, and it seems likely that more than one type of BM progenitor may be able to initiate thymopoiesis. Experimental restrictions make it impossible to definitively prove the identity of the BM precursors that normally seed the human thymus. The CD10^+^CD24^−^ population in BM is likely to represent a lymphoid progenitor that seeds the human thymus, based on finding a similar immunophenotypic subset within human thymocytes^[@R12]^. Thymocyte data presented here provides evidence that the CD10^−^CD62L^hi^ cells may be an additional or alternative thymic precursor population. It should be noted that, although CD62L expression was highest on CD34^+^CD1a^−^ progenitors, CD10^−^CD62L^hi^ BM cells are clearly not precursors of the most primitive (CD7^−^) subset of CD34^+^CD1a^−^ thymocytes. CD34^+^CD1a^−^CD7^−^ thymocytes have high myeloid and erythroid potential in clonogenic assays^[@R39]^ and do not express CD62L. It is not clear at this stage whether CD62L becomes up-regulated as CD34^+^CD1a^−^CD7^−^ MPPs differentiate into CD34^+^CD1a^−^CD7^+^ thymocytes, or that CD7 is rapidly up-regulated when CD7^−^CD62L^hi^ LMPPs engage with the thymic microenvironment. PSGL-1--P-selectin interactions are critical mediators of homing to the murine thymus^[@R40]^. As PSGL-1 was abundantly expressed on both HSC-MPP and CD10^−^CD62L^hi^ BM cells, it is possible that homing to human thymus involves the same mechanism. However, the high expression of L-selectin in the primitive CD34^+^CD1a^−^ thymocyte population and the endothelial expression of L-selectin ligands in the human thymus, specifically in the cortico-medullary region, raises the intriguing possibility that in addition to lymphocyte homing to peripheral lymphoid organs, L-selectin may have a role in progenitor homing to human thymus. We have noted that CD62L is expressed in a subset of CD34^+^lin^−^CD10^−^cells (but not CD34^+^CD10^+^ cells) in mobilized peripheral blood (data not shown), but the physiological relevance and lineage potential of this mobilized population is as yet unclear. Of note, although L-selectin interactions are not described in murine thymus homing, CD62L expression has been used to identify a population of murine BM progenitors that efficiently and rapidly reconstitutes the murine thymus upon transplantation^[@R15],[@R16]^, and an identical immunophenotypic population of cKit^+^Lin^−^Sca-1^+^CD62L^+^Rag1-deficient progenitors can be detected in the murine thymus^[@R16]^.

The reliance on CD10 expression as a marker of lymphoid commitment in previous studies of hematopoietic progenitors in human BM has until now meant that states of differentiation could only be compared between multipotent progenitors and B committed progenitors. The identification of a progenitor in human BM primed for full lymphoid differentiation, and prior to B cell commitment, now allows us to dissect the molecular regulation of the first stages of lymphoid commitment in human hematopoiesis and to understand how these processes are affected during aberrant hematopoiesis in disease states.

METHODS {#S10}
=======

Bone marrow cell isolation {#S11}
--------------------------

Normal human BM and thymic cells were obtained from healthy donors via the UCLA Pathology Tissue Core, Cincinnati Children's Hospital, or ALLCELLS according to guidelines approved by UCLA Institutional Review Board. CD34^+^ cells were enriched using the magnetic activated cell sorting (MACS) system (Miltenyi Biotec).

CD34^+^ enriched cells were incubated with combinations of the following anti-human--specific monoclonal antibodies CD34-APC-Cy7 (581) (Biolegend), or CD45RA-PE-Cy5 (HI100), CD38-APC (HIT2), CD10-PE-Cy7 (HI10a), CD62L-PE (DREG-56), CD7-PE & CD7-Pe-Cy5 (M-T701), and FITC-labeled lineage depletion antibodies: CD3 (SK7), CD14 (M2E2), CD19 (4G7), CD56 (MY31), and CD235a (GA-R2)(Becton Dickinson \[BD\]). 4',6-diamidino-2-phenylindole (DAPI) was added as a viability dye. A no-antibody control defined negative gates. Additional analyses used: CD127-Alexa 647 (HIL-7R-M21), CD117-APC (YB5.B8), CD184-APC (aka CXCR4) (12G5), PSGL1-APC (aka CD162, or SELPLG) (KPL-1), FLT3-PE (aka CD135) (4G8), CD44-APC (G44-26), CD62L-APC (DREG-56), CD90-PECy5 (5E10), HLA-DR-PE (L234) (BD). Cells were isolated on a FACSAria (355, 405, 488, 561 and 633 nm lasers) (BD Immunocytometry Systems).

B-NK Lymphoid Cultures {#S12}
----------------------

Flow cytometry isolated cells were plated in bulk on OP9 stroma in 48-well plates, or as single cells or limiting dilution on OP9 or MS5 stroma in 96-well plates using the Automated Cell Deposition Unit (ACDU). Cells were cultured in lymphoid medium \[RPMI 1640 (Irvine Scientific) with 5% FCS (Biowhittaker), 50 μM 2-mercaptoethanol (Sigma), penicillin-streptomycin, L-glutamine (Gemini Bio Products)\] with IL-7 (5 ng/mL), FLT-3Ligand (FL) (5 ng/mL) and Thrombopoietin (TPO)(5 ng/mL), (^+^/− IL-3 (5ng/mL) for first 3--5 days of culture) (R&D Systems). Clones were recorded as positive if greater than 100 cells. Cloning efficiency from single cells was defined as (\# positive wells/total wells) × 100. (see [Supplementary Table 3](#SD1){ref-type="supplementary-material"} for limiting dilution plating information)

T Lymphoid Cultures {#S13}
-------------------

Cells were plated in bulk on 6-well or 96-well plates, or as single cells or in limiting dilution (via ACDU) on established OP9-[DL1]{.ul} stroma in lymphoid medium with IL-7 (5 ng/mL), FL (5 ng/mL) and Stem Cell Factor (SCF) (1 ng/mL) (R&D)^[@R41]^.

Myelo-Erythroid Cultures and CFUs {#S14}
---------------------------------

Populations were plated on OP9 stroma in DMEM with 10% FBS, with IL-3 (5 ng/mL), FL (5 ng/mL), SCF (5 ng/mL), TPO (50 ng/mL), and Erythropoietin (4 U/mL) (R&D). CFU assays were performed as described^[@R39]^.

Lineage-specific analysis {#S15}
-------------------------

Flow cytometry of cultured cells and cells harvested from transplanted mice was performed on a Fortessa or LSRII (BD) after staining with human specific monoclonal antibodies: CD45 (HI30) (pan-human hematopoietic); HLA-A, B, C (G46-2.6)(pan-human); CD19 (4G7 and SJ25C1) (B lymphoid); CD56 (MY31)(NK cells); CD209 (DCN46)(dendritic); CD1A (HI149), CD3 (SK7), CD4 (RPA-T4), CD7(M-T701), CD8 (RPA-T8), TCR α/β (WT31)(T-lymphoid); CD235a (GA-R2) (erythroid), CD14 (M5E2), CD11B (ICRF44)(monocytic), CD14(M5E2), CD15 (W6D3), CD33 (WM53) (myeloid), CD66B (G10F5) (granulocytic) (all antibodies from BD). Data was analyzed using FlowJo software. T cell differentiation was assessed by RT-PCR of human CD45^+^ & mouse CD29^−^ cells isolated at 4--5 weeks from T lymphoid cultures.

In vivo studies {#S16}
---------------

Adult Nonobese diabetic/severe combined immunodeficiency Interleukin 2 receptor gamma chain knock out (NSG) mice (Jackson Laboratories, Bar Harbor, ME), were used for in vivo experiments according to protocols approved by the Institutional Animal Care and Use Committee of University of California Los Angeles. Adult NSG mice were irradiated (375 cGy) prior to intra-tibial injection of 3 × 10^4^ CD10^−^CD62L^hi^ cells (*n* = 3) or 2--15 × 10^4^ CD34^+^lin^−^ BM cells (*n* = 3), each with 1 × 10^5^ "carrier" cells \[irradiated (3,000 cGy) CD34^−^ UCB cells\], and euthanized 2 weeks later for flow cytometry analysis. Total human engraftment was defined as cells positive for HLA-A, B, C and humanCD45. Negative control mice received only irradiated carrier cells.

Quantitative PCR analysis {#S17}
-------------------------

After FACSAria isolation, RNA was extracted with the Qiagen RNAEsay Microkit (Qiagen) and reverse-transcribed using Omniscript RT, OLIGO DT, and RNAguard (Pharmacia Biotech). ABI Viia7 was used for real-time PCR with Taqman Mastermix and TaqMan probe based gene expression analysis assays. (List of probes, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}) (Applied Biosystems). Reactions were done in technical and biological triplicates. Nine candidate reference genes were analyzed with geNorm^plus^ software to determine optimal reference genes.^[@R42]^ Using the ΔΔC~t~ method, qPCR expression was normalized to the geometric mean of reference targets *ACTB* and *B2M.*

Single cell qPCR was performed on the Fluidigm Biomark 48.48 gene expression chip with Taqman probes, and analyzed with Fluidigm's Real-Time Software v3.0.2. β2microglobulin was used as a positive control for presence of cDNA.

Microarray Analysis {#S18}
-------------------

RNA from BM from 3 different individuals was extracted using Microkit (Qiagenand hybridized onto Affymetrix U133 Plus 2.0 Array (Affymetrix).

Robust Multichip Average (RMA)^[@R43]^ method was used to obtain normalized expression levels from the three populations. MAS5 algorithm^[@R44]^ was used to make Present, Marginal, or Absent calls for all replicates.

Replicate arrays from the three populations were hierarchically clustered using Spearman rank correlation (distance metric) and average linkage (agglomeration) method. Only probe sets called as \"Present\" by MAS5 method in all replicates in any of the three populations (24067 probes) were used for hierarchical clustering.

The number of differentially expressed genes in Venn diagrams was calculated using the R/Bioconductor^[@R45]^ package Limma^[@R46]^ at *P*-value \< 0.01 and fold change threshold +/−2. For genes with multiple probe sets, the probe set with the lowest *P* -value was chosen. Probe sets not mapped to a gene with official symbol were excluded.

Genes were considered for inclusion to the heatmap only if they were differentially expressed at a fold change of +/− 2 and significant at a *P* -value \<0.05 when compared with the other population of cells in at least one condition. Gene Set Enrichment Analysis was performed as described^[@R47]^.

For drawings, Cluster 3.0 (clustering)^[@R48]^ and Java TreeView (dendrograms, heatmaps)^[@R49]^ software was used.

Immunohistochemistry {#S19}
--------------------

Human thymi were frozen at −80°C and OCT embedded (Tissue-Tek) and 5 μm sections were stained with hematoxylin and eosin. For immunohistochemistry (IHC), sections were fixed in 10% Neutral Buffered Formalin, then incubated with primary antibody PNad (MECA79/sc-19602, 1:83, Santa Cruz Biotechnology, Inc.) and/or VE-cadherin (BV6, 1:83, Chemicon International), followed by incubation with secondary antibody anti-rat and/or anti-mouse peroxidase antibody (Vector). For fluorescence IHC, TSA Alexa 594 and/or TSA Alexa 488 was applied (Molecular Probes). For chromagen staining, DAB was applied, followed by hematoxylin (Jackson Immunoresearch). Sections were viewed with Axioimager with Apotome Imagining System (10x); images were captured with Axiocam MRm (florescence) or HRc (chromagen) (Zeiss).

Statistical analysis {#S20}
--------------------

Prism version 5 (GraphPad Software Inc) was used for statistical analysis. Two-way ANOVA compared growth potential. Total CFU output of populations, MFI and q-PCR were analyzed for mean, SEM calculation, and one-way ANOVA with a Tukey post-test. Limiting Dilution analysis used ELDA software <http://bioinf.wehi.edu.au/software/elda/>^[@R50]^.

Supplementary Material {#S21}
======================

###### 

Supplementary Figure 1. Relationship of CD7, CD38, CD10 and CD62L expression on CD34^+^lin^−^ cells and CFU potential of progenitor subsets.

Representative experiment of (**a**) CD38 and CD7 expression on CD34+lin- cells from BM (*n*=6), (**b**) CD62L and CD10 expression on CD34^+^lin^−^ BM cells (% of each subset within CD34+lin- population is shown) (*n*=30). (**c**) Table of CFUs for populations gated as in (**a**) (n=2--9). CFUs are given in \# of colonies/10^3^ BM cells plated.

Supplementary Figure 2. CD10^−^CD62L^hi^ profiles amongst different bone marrow donors

(**a**) Gating strategy for isolation of CD10^−^CD62L^hi^, CD10^+^ and CD38^−^ cell populations (**b**) Flow cytometric analysis of CD62L vs CD45RA of 20 independent human BMs. Cells were previously gated as DAPI^−^ CD34^+^ Lin^−^ CD10^−^ as shown in (**a**). (**c**) Relationship of frequency of CD10^−^CD62L^hi^ cells within the CD34^+^lin^−^CD45RA^+^ population to age. 17 BM donors in which age was known are shown (1 year to adult; *n* = 7 adults \> 25y). Note: at 1 year of age, CD34^+^lin^−^ cells are predominantly CD10^+^.

Supplementary Figure 3. T cell cultures generated from CD10^−^CD62L^hi^ cells.

Analysis of T cell cultures initiated with CD10^−^CD62L^hi^ cells (**a,b**) Unstained Flow Cytometry analysis of T Lymphoid cultures in companion to (**a**) [Figure 2c](#F2){ref-type="fig"} (Week 4 CD7-FITC, CD1A-PE, Weeks 5, 7, 8 CD8-PE, CD4-FITC) (n=6) or (**b**) [Figure 2d](#F2){ref-type="fig"} (TCRαβ-FITC, CD4-APC-Cy7, CD8-PE-Cy7, CD3-APC) (n=2). (**c**) Semi-quantitative RT-PCR analyses of T cell associated genes from total cells harvested at 4--6 weeks from 2 independent experiments. 1kb ladder shown at left of each transcript.

Supplementary Figure 4. The CD10-CD62L^hi^ population has monocytic potential in myeloid stromal co-cultures

(**a**) Flow Cytometry analysis of 2 week myelo-erythroid co-cultures (OP9 with SCF, FLT-3, TPO, IL3 and EPO) initiated with CD38-, CD10-CD62L^hi^ or CD10+ cells. Far left panels show unstained controls. Monocytes/macrophages (CD14) and dendritic cells (CD209) were detected after initial gating on CD45+ cells (not shown). FSC and SSC gating (top row) are shown to analyze small (middle row) and large (bottom row) cells separately. Glycophorin and CD66b expression were rarely detected. Data representative of 3 independent experiments. (**b**) Co-expression of myeloid (CD14, CD15 and CD33) and dendritic (CD1A+) markers in myelo-erythroid cultures initiated with CD10-CD62L^hi^ cells. Data representative of 3 independent experiments.

Supplementary Figure 5. Additional in vivo reconstitution data.

Flow cytometry analysis of NSG mice transplanted with human BM populations and analyzed 2wk post transplant. (**a-d**) Data from 5 additional animals not included in [Fig 3f](#F3){ref-type="fig"}. Mouse \#4 received 100,000 irradiated CD34^−^ carrier cells only (negative control), Mice \#5 and \#6 received 30,000 CD34^+^lin^−^CD10^−^ CD62L^hi^ cells, Mouse \#7 received 150,000 CD34^+^lin^−^ cells, and Mouse \#8 received 30,000 CD34^+^lin^−^ cells. **(a)** Unstained controls for PE (hCD45) and PE-Cy7 (HLA-class 1), **(b, c)** Fluorescence minus one (FMO) controls from composite of cells from animals \#7 and \#8, **(b)** is gated from FSC vs SSC as shown in (**a**), (**c**) is gated on CD45^+^HLA^+^ cells as shown in (**d**). (**d**) Human engraftment shown top row as hCD45^+^ & HLA-class 1^+^ cells, bottom row shows B (CD19+) cells and myeloid (CD14, CD15, & CD33+) cells from gated human cells.

Supplementary Figure 6. Global gene expression analysis places CD10^−^CD62L^hi^ population in intermediate position between CD38^−^and CD10^+^,with similar profile to umbilical cord blood CD34^+^CD38^−^CD7^+^ lymphoid progenitors

Microarray datasets from three independent BM samples. (**a**) Hierarchical clustering of global gene expression using Spearman rank correlation and average linkage method. (**b**) Venn Diagram showing pair-wise comparisons of global gene expression. Shown are number of genes that are \> 2 fold differentially up-regulated or down-regulated relative to CD38^−^, p\<0.01. (**c**) Gene Set Enrichment Analysis (GSEA) comparing gene expression between BM CD10^−^CD62L^hi^ and BM CD38^−^ and published CD34^+^CD38^−^CD7^+^ UCB^[@R20]^. Overall the set of genes down-regulated in BM CD10^−^CD62L^hi^ (LMPP) compared to BM CD38^−^ (HSC-MPP) was similar to the set of genes down-regulated in UCB CD34^+^CD38^−^CD7^+^ (MLP) compared to UCB CD34^+^CD38^−^CD7^−^ (HSC-MPP) from Hoebeke et al. (FDR q-value 1.6180314E-4, Normalized Enrichment Score −2.398794).

Supplementary Figure 7. Stages of lymphoid priming and B cell commitment in human bone marrow.

(**a**, **b**) Changes in relative expression of key cytokine receptors in BM progenitor populations listed above, (**a**) protein expression by flow cytometry and (**b**) gene expression by array and/or qPCR. Note, although *FLT3* transcripts are increased in the CD10^−^CD62L^hi^ LMPP population, expression by flow cytometry is similar in HSC-MPP and LMPP. (**c**) Proposed model of progenitor relationships during early stages of lymphoid commitment in human bone marrow. CD34^+^lin^−^ CD10^+^ cells are predominantly B cell progenitors (BCP) whereas CD10-CD62L^hi^ cells readily generate all three lymphoid lineages; dashed lines represent less prominent lineage differentiation pathways.

Supplementary Table 1. Colony Forming Unit assay raw data

(**a**) Raw data for Colony Forming Unit Assays. All data is from subsets shown of human BM CD34+ Lin- cells. Each experiment represents duplicate plates from one flow cytometry sorted BM. (**b**) *P-*values of unpaired t-tests comparing CFU output from CD10^−^ CD62L^hi^ to each population shown (*N*=number of times that cell population was tested using a different donor, all in duplicate).

Supplementary Table 2. List of qPCR probes

List of ABI Taqman Probes and amplicon size used for qPCR analysis.

Supplementary Table 3. Set up for limiting dilution experiments

Number of wells seeded at each cell number for limiting dilution analysis on (**a**) MS5 stroma (n=3 independent samples) (see [Fig 3a](#F3){ref-type="fig"}) or (**b**) OP9DL1 stroma (n=3 independent samples) (see [Fig 3b](#F3){ref-type="fig"})
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![Identification of BM progenitors that lack myeloid and erythroid clonogenic potential\
(**a**) CD7 and CD10 expression on CD34^+^lin^−^Bone Marrow (BM) cells (representative of 7 independent experiments). Error bars represent SEM. \* = p\<0.050, \*\* = p\<0.010, \*\*\* = p\<0.001 (**b**) Myeloid and erythroid clonogenic output in methylcellulose assay of the CD34^+^lin^−^ subsets shown. (Total n=4, CD10^−^CD7^−^ and CD10^−^CD7^+^ n=2, CD10^+^ n=5) (**c**) Flow cytometry isolation strategy of CD34^+^lin^−^CD45RA^+^10^+^ ("CD10^+^") and CD34^+^lin^−^CD45RA^+^CD10^−^CD62L^hi^ ("CD10^−^CD62L^hi^ "). Over 30 independent BMs examined (see also [Fig S3](#SD1){ref-type="supplementary-material"}). (**d**) Myeloid and erythroid clonogenic capacity of each subset shown. All populations shown, including "total" are CD34^+^lin^−^. (p\<0.001 comparing CD10^−^CD45RA^+^ and CD10^−^CD45RA^+^CD62L^hi^; frequency was also significantly decreased in CD10^−^ CD62L^hi^ and CD10^+^ relative to all other populations shown, see [Table S1a, b](#SD1){ref-type="supplementary-material"}). IL3R^lo^ CD45RA^−^("CMP"), IL3R^−^CD45RA^−^("MEP"), and IL3R^lo^ CD45RA^+^ ("GMP"). (**e**) CD62L expression on CD34^+^lin^−^populations shown, representative of over 20 independent BMs. (f) Flow cytometry of gated CD34^+^lin^−^CD10^−^ cells showing lack of CD7 expression on CD62L^hi^ cells, representative of 5 independent BM. \[For all phenotypes, lin^−^ is defined as negative for CD3, CD14, CD15 (aka FUT4), CD19, CD56 (aka NCAM1), and CD235a (aka GYPA)\].](nihms396288f1){#F1}

![Lympho-myeloid potential of bone marrow progenitors\
Analysis of B-NK cultures (**a,b**) and T cell cultures (**c,d,e**) initiated with CD10^−^CD62L^hi^ or CD10^+^ cells. (**a**) Flow Cytometry analysis of 4 week B-NK lymphoid cultures (OP9 with SCF, FLT-3, TPO); CD19 (B lymphoid) CD56 (NK cells); (one representative of 10 independent experiments). (**b**) Cell output (fold increase from Day 0) of CD34^+^lin^−^ populations in B-NK lymphoid conditions. (**c,d**) Flow Cytometry analysis of T Lymphoid cultures (OP9-DL1 stroma with SCF, FLT-3, and IL7.) (**e**) CD10^−^ CD62L^hi^ cells generate significantly more cells in T cell conditions than do CD10^+^ cells. Shown is fold increase from Day 0 of total cells generated from bulk cultures of CD34^+^lin^−^populations shown (\* p \<0.038, n=6 experiments). (**f**) Cell growth (fold increase from Day 0) of BM CD34^+^lin^−^ populations in myelo-erythroid co-culture (OP9 stroma with IL-3, TPO, SCF, EPO, and FLT-3). HSC (CD34^+^lin^−^CD38^−^ cells) generate significantly more cells in myelo-erythroid conditions than either CD10^−^CD62L^hi^ or CD10^+^ cells (\*\* p \<0.0001 for CD38^−^ vs either CD10^−^ CD62L^hi^ or CD10^+^. p = 0.49 for CD10^−^ CD62L^hi^ vs CD10^+^, n=3 independent experiments).](nihms396288f2){#F2}

![Lineage potential of CD10^−^ CD62L^hi^ cells by in vitro clonal analyses and in vivo transplantation studies\
**(a,b**) Limiting dilution analysis of CD10^−^ CD62L^hi^ cells grown in either : (**a**) B-NK conditions (cloning efficiency 1 in 5.3, 95% confidence interval 1 in 4.4--6.4, n=3 experiments), or (**b**) T cell conditions (cloning efficiency 1 in 5.6, 95% confidence interval 1 in 4.6--6.9, n=3 experiments). (**c**) Lineage analysis of clones from single CD10^−^ CD62L^hi^ or CD10^+^ cells in B-NK lymphoid co-culture. Shown is percentage of wells with clonal growth containing B cells, NK cells or both. (**d**) FACS analysis of clones generated in B-NK conditions from 1--3 CD10^−^ CD62L^hi^ cells showing NK (CD56^+^), myeloid (CD14 & CD15) and dendritic (CD1a) potential from one clone (first two panels); B (CD19^+^) and dendritic (CD1a^+^) (third panel); co-expression of myeloid and dendritic markers from single cell clone (panel far right). (**e**) FACS analysis of a single clone generated in T conditions showing T (CD4^+^CD8^+^) and myeloid (CD4^dim^CD14^+^&CD15^+^) potential. (**f)** FACS analysis of NSG mouse BM analyzed 2wk post transplant with 30,000 CD34^+^lin^−^CD10^−^ CD62L^hi^ cells (center) or 150,000 CD34^+^lin^−^ cells (right). Negative control mouse (left) received 100,000 irradiated CD34^−^ carrier cells only. Human engraftment shown top row as hCD45^+^HLA-Class 1^+^ cells, middle row shows B (CD19^+^) cells and myeloid (CD14, CD15, & CD33^+^) cells from gated human cells, bottom row shows backgating of B and Myeloid cells shown in each panel above. (**g**) Compiled data from transplant experiments (n=3 mice each group).](nihms396288f3){#F3}

![CD10^−^CD62L^hi^ cells represent an intermediate stage of differentiation between HSC and CD10^+^ progenitors\
(**a**) Flow Cytometry showing co-expression of key cell surface markers on three CD34^+^lin^−^populations. Bar graph shows Mean Florescent Intensity (MFI) summarized from 2 or 3 independent samples for each marker, n=14 for CD38. (\* = p\<0.010, \*\* = p\<0.001) (**b**) Flow Cytometry analysis of one week B-NK lymphoid cultures initiated with CD38^−^, CD10^−^CD62L^hi^ or CD10^+^ cells. (**c**) Unsupervised whole genome Principal Component Analysis of three independent BM samples.](nihms396288f4){#F4}

![CD10^−^CD62L^hi^ cells represent a distinct progenitor population with a unique expression profile that combines hematopoietic stem cell and early lymphoid genes\
(**a**) Gene expression of transcription factors or (**b**) cytoplasmic and cell surface molecules. Genes included in cluster designations of heatmap were all more than 2 fold differentially regulated in pair-wise comparisons (p \<0.05), and based on statistical analysis (not heatmap appearance) defined as Cluster 1: upregulated only in CD38^−^, and other 2 populations equivalent i.e. CD38^−^ \> (CD10^−^CD62L^hi^ = CD10^+^); Cluster 2: CD38^−^ \>CD62L^hi^ \>CD10^+^; Cluster 3: (CD38^−^ = CD10^−^CD62L^hi^) \>CD10^+^; Cluster 4: CD10^−^CD62L^hi^ \> (CD38^−^ =CD10^+^); Cluster 5: (CD10^−^CD62L^hi^ = CD10^+^) \>CD38^−^; Cluster 6: CD10^+^ \> (CD10^−^CD62L^hi^ = CD38^−^). (**c**) qPCR for selected genes, each normalized to CD10^−^CD62L^hi^ (n= 3 biological replicates, \* = p≤0.050, \*\* = p\<0.010, \*\*\* = p\<0.001) mean ± SEM (**d**) qPCR assay of expression of selected genes in single cells using Fluidigm Biomark 48.48 analyzer (bars represent percentage of single cells tested expressing gene transcript, n=13 cells analyzed per each gene).](nihms396288f5){#F5}

![High CD62L expression and recruitment to human thymus\
(**a**) Relative expression of homing molecules on CD10^−^CD62L^hi^ cells (green) and CD10^+^ cells (red) by FACS (gated as CD34^+^lin^−^). Unstained (black) (**b**) RNA expression of *CCR7* in CD38^−^, CD10^−^CD62L^hi^ and CD10^+^ cells by qPCR (n=3 biological replicates, \* = p≤0.050, \*\* = p\<0.010, \*\*\* p\<0.001) mean ± SEM. (**c**) CD62L expression in human CD34^+^ and CD34^−^ thymocytes (upper) and CD34^+^CD1A^+^ and CD34^+^ CD1A^−^ thymocytes (lower) by flow cytometry. (**d**) Chromagen immunohistochemistry showing MECA-79 staining at the cortico-medullary junction. (**e**, **f, g**) Fluorescence immunohistochemistry of same region as in (**d**) showing (**e**) MECA79 co- staining with (**f**) VE-Cadherin^+^ blood vessels. (**h, i, j**) Fluorescence immunohistochemistry showing (**h**) MECA79 co-staining in a subset of (**i**) P-Selectin blood vessels at the cortico-medullary junction.](nihms396288f6){#F6}
